

Institutional Biosafety Committee - Regular Meeting

Thursday, May 07, 2026

Zoom

Meeting Minutes

VOTING MEMBERS PRESENT:	G. Babcock, K. Burns, J. Corcoran, G. Dean, D. Elsaesser, M. Espinola, S. Kasper, F. Schaefer, E. Serafin
VOTING MEMBERS NOT PRESENT:	S. Apewokin, R. Larson, E. Otten, T. Rausch
AD HOC MEMBERS/CONSULTANTS/GUESTS:	G. Deepe, T. Gulley, A. Perry, J. Strasser
IBC STAFF:	D. Healy, B. Kesavalu

K. Burns convened the meeting at 11:58 p.m.

- I. **Conflicts of Interest** - No conflicts were identified.
- II. **Minutes** - Minutes from the previous IBC meeting (04/02/26) was approved (9: YES/0: NO/0: Abstained)
- III. **Old Business** - No old business to discuss
- IV. **New Business**

A. Primary Protocols (2 protocols)

IBC Protocol Number	PI	Type of Submission	IBC Items	
1. 26-04-24-01	Rojan	New Clinical	Reovirus (REO 33)	
IBC Requests:	<u>IBC Form</u> 1. Provide BBP transcripts for clinical staff; 2. Section II. B - Expand the description of Pelareorep (Reovirus) including agent's characteristics, clinical manifestation and what makes it a good candidate for cancer treatment; 3. Section II. B - Indicate what FOLFIRI, ORR, RECIST 1.1. OS, PFS EOS stand for; 4. Section II. C. 4 - In "Additional Information" state again that no vectors will be given to patients and that a wild type reovirus is given to patients instead.			
	Motion	Approve upon modifications addressing outlined issues.		
Voting Result & Dual Use	YES: 9	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
2. 24-03-08-02	Hyacinth	Amendment	BSL2	<u>in vivo:</u> AAV, retroviral and rabies viral vectors AMENDMENT: <u>in vitro:</u> lentiviral vector and HDM (primary cells, blood, tissues)
IBC Requests:	- Lab staff need to complete their BBP, Viral vector, and BSC trainings; <u>Main Form – General Safety:</u> - Remove 2024 from the title; Section I. C - Review staff list and update it accordingly and add additional new staff information;			

B. Secondary Protocols (3 protocols)

IBC Protocol Number	PI	Type of Submission	IBC Items	
1. 26-04-21-01	Latif	Renewal Clinical	CAR T cells (IMPT-314: LYL314-101)	
IBC Requests:	<u>IBC Form</u> 1. Provide BBP transcripts for clinical staff; 2. Section II. B - Spell out NHL when mentioned for the first time; 3. Section III. B – Remove old dates and provide the last certification dates for the BSCs.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & Dual Use	YES: 9	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
2. 26-04-15-01	Kossack	New	BSL1	Transgenic Zebrafish (Breeding)
IBC Requests:	<u>Main Form – General Safety:</u> 1. Section I. B - provide UC Mail Code. If no office phone and lab phone are present, enter "N/A"; 2. Section I. B - Secondary contact's Last Name is entered in the wrong place, correct it and include her job title; 3. Section II. B - Describe the Zebrafish's genetic modification(s). <u>Form D – Biohazard in Animals:</u> 4. Section I - Provide the number of your IACUC protocol.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & Dual Use	YES: 9	NO: 0	Abstained: 0	Dual Use? No

IBC Protocol Number	PI	Type of Submission	Biosafety Level	IBC Items
3. 26-04-06-01	Zhang P	Renewal	BSL2	<i>in vitro</i> : <i>Pseudomonas aeruginosa</i> , <i>Acinetobacter baumannii</i> , <i>Enterococcus faecalis</i> , <i>Escherichia coli</i> , <i>Staphylococcus epidermidis</i> , <i>Staphylococcus aureus</i> , <i>Trichophyton rubrum</i> , <i>Candida albicans</i> , <i>Botrytis cinerea</i> and HDM (cell lines)
IBC Requests:	<u>Main Form – General Safety:</u> 1. Section II. B - Include the project involving human cancer cells; 2. Section II. B - Spell out MICs and MBCs; 3. Section II. B - Provide an example for point of need applications. <u>Form B – Microbial/Infectious Agents</u> 4. Agent #1 - Second sentence - Replace "Biosafety Level" with "Risk Group" ; 5. Agent #4 - "Risk Group" should be RG1; 6. Agents #5, #9 and #10 - "Biosafety Level" should read "BSL2"; <u>Form C – Human and NHP Derived Materials:</u>			

	7. Section II. A – Define “IR” and “PUNP” when first mentioned.			
Motion	Approve upon modifications addressing outlined issues.			
Voting Result & Dual Use	YES: 9	NO: 0	Abstained: 0	Dual Use? No

- V. Protocol Updates** - March 26th to April 30th (17 protocols)
1. IBC# 24-01-02-01 - PI: Waltz - Personnel
 2. IBC# 25-02-17-01 - PI: Zhang, Xiang - Personnel
 3. IBC# 25-02-17-01 - PI: Nannu Shankar - Amendment: *in vitro* environmental samples and personnel
 4. IBC# 25-03-19-01 - PI: Owens - Personnel
 5. IBC# 25-12-12-02 - PI: Kotagiri - Add cells and sorting
 6. IBC# 24-11-18-01 - PI: Zhang JM - Personnel
 7. IBC# 25-04-06-01 - PI: Xia - Personnel
 8. IBC#24-01-20-02 - PI: Scaglioni - Personnel
 9. IBC# 25-04-15-01 - PI: Wise-Draper - Personnel
 10. IBC# 25-05-23-01 - PI: Lewis - Amendment: *in vivo*: HDM(PDX) and personnel
 11. IBC# 23-09-13-01 - PI: Barrile - Personnel
 12. IBC# 25-01-16-01 - PI: Morrow - Personnel
 13. IBC# 23-09-14-01 - PI: Schutte - Location
 14. IBC# 24-03-06-01 - PI: Luo - Personnel
 15. IBC# 24-03-13-01 - PI: Shirokawa - Personnel
 16. IBC# 24-02-23-01 - PI: Apewokin - Amendment: *in vitro* *E. coli* and location
 17. IBC# 26-02-06-01 - PI: Kotarsky - Location

- VI. Reports**
- A. IBC and BSO of (M. Espinola)
On April 3rd, the NIH/OSP acknowledged receipt of the incident notification involving T. Thompson and required no further information.

- VII. Educational Materials/Updates**
- A. **Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.** Regeneron, April 2026.

K. Burns adjourned the meeting at 12:21 p.m.

